Articles by William Looney - Pharmaceutical Executive

ADVERTISEMENT

Articles by William Looney

Dividing Lines

Apr 1, 2014

Three examples from Pharm Exec's coverage this month show that, in our industry, there are always two sides—at least—to every question.

Population Health: The Call to Community

Mar 11, 2014

Population health is the foundation for much of what is truly new in US health reform. Pharm Exec talks to Dr. David Nash, Dean of the Jefferson Medical University School of Population Health.

The Community Ethic

Mar 1, 2014

Regardless of how you define it, partnership is also an institutional necessity as big Pharma adjusts to disruptive changes in the way health services are financed and delivered. A revolution in the making, where legislation combined with market forces as well as community and stakeholder advocacy are adding fresh momentum to a population-based approach to health practice. Population health focuses on a system built around three pillars of care: preventive care, primary care, and coordinated care, all driven by a single performance metric, which is value, as evidenced through quality and outcomes. Executing around this integrative model depends entirely on partnerships, especially with non-traditional players like the physician assistant.

Anna Protopapas: Takeda's Oncology Taskmaster

Feb 3, 2014

Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge—and a lead position in the hotly contested search to make cancer a treatable disease.

Takeda's Oncology Taskmaster

Feb 1, 2014

Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge—and a lead position in the hotly contested search to make cancer a treatable disease.

A Spark From GSK

Feb 1, 2014

Today, there is promise in new approaches that rely on the "other language of biology," using the human body's own circuitry of cells and nerves to induce precisely targeted therapeutic effects against a range of debilitating diseases.

Russian Innovation: A Higher Mark

Feb 1, 2014

For the first time, the spotlight shines on Russia's potential in biotechnology and pharma products

Russia's Bet on Biopharma

Jan 21, 2014

Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector, writes William Looney.

For Russia—Tough Love

Jan 21, 2014

Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exst. Drugs were still classified as chemicals, developed from the random screening of many thoughts.

ADVERTISEMENT

Click here